Patents Assigned to Novartis Vaccines and Diagnostics
  • Conjugation of streptococcal capsular saccharides
    Patent number: 8513392
    Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: August 20, 2013
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventor: Francesco Berti
  • MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES
    Publication number: 20130195923
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 1, 2013
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES
    Publication number: 20130195898
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Application
    Filed: September 15, 2012
    Publication date: August 1, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Genes Differentially Expressed in Breast Cancer
    Publication number: 20130196314
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 1, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Tissue culture system for production of hepatitis C virus
    Patent number: 8481050
    Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: July 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
  • Chlamydial antigens
    Patent number: 8481057
    Abstract: The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from Chlamydia trachomatis that are expressed on the cell surface and so are ideal for use in immunization as well as combinations of these antigens.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 9, 2013
    Assignee: Novartis Vaccines & Diagnostics SRL
    Inventors: Guido Grandi, Lehutova Livia
  • Complement factor H-based assays for serum bactericidal activity against
    Patent number: 8476032
    Abstract: Assays for detection of bactericidal anti-Neisserial antibodies using a factor H polypeptide having a human amino acid sequence that mediates binding to Neisserial factor H binding protein (fHBp) are provided, as well as non-human animal models of Neisserial infection.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: July 2, 2013
    Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, The University of Massachusetts
    Inventors: Dan M. Granoff, JoAnne Welsch, Sanjay Ram
  • Immunogenic reagents from west nile virus
    Patent number: 8475808
    Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: July 2, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes, Yiu-Lian Fong
  • Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics
    Patent number: 8470334
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: June 25, 2013
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W. Barnett, Indresh K. Srivastava
  • Peptides presenting an epitope of a domain of factor H binding protein and methods of use
    Patent number: 8470340
    Abstract: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: June 25, 2013
    Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, Universita degli Studi del Molise
    Inventors: Peter Beernink, Franco Felici, Dan M. Granoff
  • Pancreatic cancer genes
    Patent number: 8460873
    Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: June 11, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Giulia Kennedy
  • NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B
    Publication number: 20130129740
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Application
    Filed: August 30, 2012
    Publication date: May 23, 2013
    Applicants: J. Craig Venter Institute, Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Hervé Tettelin, Claire Fraser
  • Multiple vaccination including serogroup C meningococcus
    Patent number: 8444992
    Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: May 21, 2013
    Assignee: Novartis Vaccines and Diagnostics GmbH
    Inventor: Astrid Borkowski
  • Nucleic acids and proteins from groups A and B
    Patent number: 8431139
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: April 30, 2013
    Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter Institute
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • IMIDAZOQUINOLINE COMPOUNDS
    Publication number: 20130096103
    Abstract: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).
    Type: Application
    Filed: June 19, 2012
    Publication date: April 18, 2013
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Nicholas VALIANTE, Feng Xu, Xiaodong Lin, Daniel Chu, Xiaojing Michael Wang
  • NOROVIRUS AND SAPOVIRUS ANTIGENS
    Publication number: 20130095552
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Application
    Filed: November 27, 2012
    Publication date: April 18, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Novartis Vaccines and Diagnostics, Inc.
  • Substituted benzazoles and methods of their use as inhibitors of RAF Kinase
    Patent number: 8415382
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Methods and Reagents for Diagnosing Hantavirus Infection
    Publication number: 20130085264
    Abstract: Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.
    Type: Application
    Filed: December 5, 2012
    Publication date: April 4, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Novartis Vaccines and Diagnostics, Inc.
  • ADP-ribosylating toxin from listeria monocytogenes
    Patent number: 8398986
    Abstract: An ADP-ribosylating toxin from Listeria monocytogenes is disclosed, together with mutant toxins and uses therefor. There is only a low level of sequence identity between this toxin and known toxins such as the iota toxin from Clostridium perfringens.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: March 19, 2013
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventor: Vega Masignani
  • CULTIVATION OF DISPERSED MYCOBACTERIA
    Publication number: 20130059364
    Abstract: The present invention relates to a culture medium for disperse mycobacteria comprising at least one detergent and an antifoam agent, whereby said antifoam agent is a member of the silicone family. In addition, the invention provides for methods for the activation of dipressed mycobacteria, for obtaining a standardized mycobyterial culture or for the production of (a), purified protein derivates(s) (PDD) which comprise the cultivation of mycobacteria in the active medium disclosed herein. Furthermore, the use of standardized mycobacterial cultures obtained by the method of the invention for the preparation of pharmaceutical or diagnostic compositions is described.
    Type: Application
    Filed: July 3, 2012
    Publication date: March 7, 2013
    Applicant: Novartis Vaccines and Diagnostics GmbH
    Inventors: Guido Dietrich, Erika Hundt, Heinz Weber